ARS Pharmaceuticals (SPRY) Receivables (2023 - 2026)

ARS Pharmaceuticals has disclosed Receivables across 4 years of filings, most recently posting $28.7 million for Q1 2026.

• Receivables for Q1 2026 came in at $28.7 million, up 179.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.7 million (up 179.19% YoY), and the FY2025 annual result was $25.3 million, up 169.45% from the prior year.
• Receivables came in at $28.7 million for Q1 2026 at ARS Pharmaceuticals, up from $25.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $40.7 million in Q3 2025 to a low of $652000.0 in Q4 2023.
• The 4-year median for Receivables is $17.8 million (2025), against an average of $17.9 million.
• Peak annual rise in Receivables reached 4302.16% in 2025, while the deepest fall reached 169.45% in 2025.
• ARS Pharmaceuticals' Receivables stood at $652000.0 in 2023, then soared by 1342.79% to $9.4 million in 2024, then jumped by 169.45% to $25.3 million in 2025, then rose by 13.08% to $28.7 million in 2026.
• The last three Receivables figures came in at $28.7 million (Q1 2026), $25.3 million (Q4 2025), and $40.7 million (Q3 2025), per Business Quant data.